

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Dec-2016  
 Document Type: USP Monographs  
 DocId: GUID-B01D3BC7-9A68-4A88-80AC-BE965F2F6B78\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M53673\\_01\\_01](https://doi.org/10.31003/USPNF_M53673_01_01)  
 DOI Ref: b2dam

© 2025 USPC  
 Do not distribute

## Metronidazole Gel

### DEFINITION

Metronidazole Gel contains NLT 90.0% and NMT 110.0% of the labeled amount of metronidazole ( $C_6H_9N_3O_3$ ).

### IDENTIFICATION

- **A.** The UV spectrum of the metronidazole peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

- **PROCEDURE**

**Solution A:** Methanol and water (20:80)

**Solution B:** Methanol

**Mobile phase:** See [Table 1](#).

**Table 1**

| Time<br>(min) | Solution A<br>(%) | Solution B<br>(%) |
|---------------|-------------------|-------------------|
| 0             | 100               | 0                 |
| 10.0          | 100               | 0                 |
| 15.0          | 10                | 90                |
| 15.1          | 100               | 0                 |
| 20.0          | 100               | 0                 |

**System suitability solution:** 0.6 µg/mL of [USP Metronidazole RS](#) and 0.6 µg/mL of [USP Tinidazole Related Compound A RS](#) in *Solution A*

**Standard solution:** 30 µg/mL of [USP Metronidazole RS](#) in *Solution A*

**Sample stock solution:** Nominally 300 µg/mL of metronidazole in *Solution A* prepared as follows. Transfer a portion of Gel to a suitable volumetric flask. Add *Solution A* equivalent to 50% of the flask volume and sonicate or vortex until dissolved. Dilute with *Solution A* to volume. [NOTE—On the basis of formulation, if necessary, centrifuge a portion of the solution at 3000 rpm for 10 min and pass a portion of the supernatant through a filter of 0.45-µm pore size. Use the filtrate.]

**Sample solution:** Nominally 30 µg/mL of metronidazole in *Solution A* prepared from the *Sample stock solution*

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 319 nm. For *Identification test A*, use a diode-array detector in the range of 210–500 nm.

**Column:** 4.6-mm × 15-cm; 5-µm packing L7

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection volume:** 30 µL

### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

### Suitability requirements

**Resolution:** NLT 2.0 between metronidazole and tinidazole related compound A, *System suitability solution*

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of metronidazole ( $C_6H_9N_3O_3$ ) in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of metronidazole from the *Sample solution*

$r_S$  = peak response of metronidazole from the *Standard solution*

$C_S$  = concentration of [USP Metronidazole RS](#) in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_U$  = nominal concentration of metronidazole in the *Sample solution* ( $\mu\text{g/mL}$ )

**Acceptance criteria:** 90.0%–110.0%

#### IMPURITIES

- **ORGANIC IMPURITIES**

**Solution A, Solution B, Mobile phase, and Chromatographic system:** Proceed as directed in the Assay.

**Standard solution:** Use the *System suitability solution* from the Assay.

**Sample solution:** Use the *Sample stock solution* from the Assay.

#### System suitability

**Sample:** *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

#### Suitability requirements

**Resolution:** NLT 2.0 between metronidazole and tinidazole related compound A

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of tinidazole related compound A in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of tinidazole related compound A from the *Sample solution*

$r_S$  = peak response of tinidazole related compound A from the *Standard solution*

$C_S$  = concentration of [USP Tinidazole Related Compound A RS](#) in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_U$  = nominal concentration of metronidazole in the *Sample solution* ( $\mu\text{g/mL}$ )

Calculate the percentage of each individual unspecified impurity in the portion of Gel taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of each unspecified impurity from the *Sample solution*

$r_S$  = peak response of metronidazole from the *Standard solution*

$C_S$  = concentration of [USP Metronidazole RS](#) in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_U$  = nominal concentration of metronidazole in the *Sample solution* ( $\mu\text{g/mL}$ )

**Acceptance criteria:** See [Table 2](#).

**Table 2**

| Name                                | Relative Retention Time | Acceptance Criteria, NMT (%) |
|-------------------------------------|-------------------------|------------------------------|
| Tinidazole related compound A       | 0.76                    | 0.2                          |
| Metronidazole                       | 1.0                     | —                            |
| Any individual unspecified impurity | —                       | 0.3                          |
| Total impurities                    | —                       | 1.0                          |

**PERFORMANCE TESTS**

- [MINIMUM FILL \(755\)](#): Meets the requirements

**SPECIFIC TESTS**

- [pH \(791\)](#): The apparent pH determined potentiometrically is between 4.0 and 6.5.

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE**: Preserve in laminated collapsible tubes at controlled room temperature.

- [USP REFERENCE STANDARDS \(11\)](#):

[USP Metronidazole RS](#)

[USP Tinidazole Related Compound A RS](#)

2-Methyl-5-nitroimidazole.

C4H5N3O2 127.10

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question             | Contact   | Expert Committee          |
|----------------------------|---|---------------------------|
| METRONIDAZOLE GEL          | <a href="#">Documentary Standards Support</a>                               | SM12020 Small Molecules 1 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM12020 Small Molecules 1 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(4)

**Current DocID:** [GUID-B01D3BC7-9A68-4A88-80AC-BE965F2F6B78\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M53673\\_01\\_01](https://doi.org/10.31003/USPNF_M53673_01_01)

**DOI ref:** [b2dam](#)